Blueprint Medicines to Present at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Blueprint Medicines Corporation (NASDAQ: BPMC) has announced its participation in several upcoming investor conferences. These include:
- Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30 p.m. ET.
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 8:50 a.m. ET.
- JMP Securities Life Sciences Conference on June 16, 2021, at 1:00 p.m. ET.
Live webcasts will be available on the company's website, with replays accessible for 30 days post-presentation.
Details
News Market Reaction – BPMC
The recorded move for BPMC in the trading session of this news was +0.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.
- Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 p.m. ET.
- Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 8:50 a.m. ET.
- JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 1:00 p.m. ET.
A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-301298404.html
SOURCE Blueprint Medicines Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.